Merit Medical Systems - MMSI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $105.60
  • Forecasted Upside: 7.51%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$98.22
▲ +1.95 (2.03%)

This chart shows the closing price for MMSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merit Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MMSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MMSI

Analyst Price Target is $105.60
▲ +7.51% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Merit Medical Systems in the last 3 months. The average price target is $105.60, with a high forecast of $127.00 and a low forecast of $87.00. The average price target represents a 7.51% upside from the last price of $98.22.

This chart shows the closing price for MMSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Merit Medical Systems. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/21/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/20/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$103.00 ➝ $120.00
12/9/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$125.00 ➝ $127.00
10/31/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$114.00 ➝ $114.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$109.00 ➝ $109.00
10/31/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$107.00 ➝ $109.00
10/18/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$114.00 ➝ $114.00
9/20/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$100.00 ➝ $114.00
9/16/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$85.00 ➝ $103.00
9/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00
9/16/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$92.00 ➝ $103.00
9/9/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$100.00 ➝ $110.00
8/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$94.00 ➝ $105.00
8/5/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$87.00 ➝ $92.00
8/2/2024Piper SandlerBoost TargetOverweight ➝ Overweight$97.00 ➝ $100.00
8/2/2024Needham & Company LLCBoost TargetBuy ➝ Buy$93.00 ➝ $94.00
7/16/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$100.00 ➝ $100.00
7/2/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$100.00 ➝ $100.00
7/2/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$102.00 ➝ $125.00
7/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$85.00 ➝ $93.00
6/28/2024Baird R WUpgradeStrong-Buy
6/28/2024Robert W. BairdInitiated CoverageOutperform$96.00
5/1/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$112.00 ➝ $102.00
5/1/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$98.00 ➝ $100.00
5/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$95.00 ➝ $97.00
5/1/2024Needham & Company LLCLower TargetBuy ➝ Buy$88.00 ➝ $85.00
4/16/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$98.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$88.00
4/11/2024CL KingInitiated CoverageBuy$88.00
2/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$82.00 ➝ $87.00
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$81.00 ➝ $88.00
2/29/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$96.00 ➝ $98.00
2/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$102.00 ➝ $112.00
2/7/2024Bank of AmericaInitiated CoverageNeutral$87.00
1/30/2024Raymond JamesBoost TargetOutperform ➝ Outperform$84.00 ➝ $89.00
1/12/2024Piper SandlerBoost TargetOverweight ➝ Overweight$88.00 ➝ $95.00
12/21/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$76.00 ➝ $100.00
12/21/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$100.00
10/27/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$95.00 ➝ $96.00
10/27/2023Needham & Company LLCLower TargetBuy ➝ Buy$96.00 ➝ $81.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00
8/28/2023Canaccord Genuity GroupLower TargetHold ➝ Hold$86.00 ➝ $70.00
8/16/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$95.00
7/26/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00
7/21/2023Piper SandlerBoost TargetOverweight$85.00 ➝ $92.00
6/9/2023Barrington ResearchBoost Target$90.00 ➝ $95.00
6/9/2023Needham & Company LLCBoost Target$90.00 ➝ $96.00
5/8/2023Raymond JamesBoost Target$88.00 ➝ $93.00
4/27/2023Barrington ResearchBoost Target$78.00 ➝ $90.00
4/27/2023Needham & Company LLCBoost Target$84.00 ➝ $90.00
4/27/2023Wells Fargo & CompanyBoost Target$74.00 ➝ $81.00
4/27/2023Piper SandlerBoost Target$77.00 ➝ $85.00
4/27/2023Raymond JamesBoost Target$86.00 ➝ $88.00
4/19/2023Needham & Company LLCBoost TargetBuy$78.00 ➝ $84.00
4/17/2023Raymond JamesBoost TargetOutperform$80.00 ➝ $86.00
4/12/2023Barrington ResearchReiterated RatingOutperform$78.00
2/23/2023Barrington ResearchReiterated RatingOutperform$78.00
2/23/2023Piper SandlerBoost TargetOverweight$73.00 ➝ $77.00
2/23/2023Needham & Company LLCBoost TargetBuy$73.00 ➝ $78.00
2/23/2023Raymond JamesBoost TargetOutperform$72.00 ➝ $80.00
12/20/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$73.00 ➝ $72.00
11/7/2022Canaccord Genuity GroupBoost Target$69.00 ➝ $73.00
10/28/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$63.00 ➝ $69.00
10/27/2022Raymond JamesBoost TargetOutperform$71.00 ➝ $72.00
10/27/2022Piper SandlerBoost Target$70.00 ➝ $73.00
10/14/2022Canaccord Genuity GroupLower Target$69.00 ➝ $63.00
9/2/2022Canaccord Genuity GroupBoost TargetBuy$67.00 ➝ $69.00
8/1/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$74.00 ➝ $67.00
7/1/2022Piper SandlerLower Target$75.00 ➝ $70.00
4/28/2022Barrington ResearchLower Target$82.00 ➝ $78.00
2/25/2022Barrington ResearchBoost TargetBuy$78.00 ➝ $82.00
2/25/2022Raymond JamesLower TargetOutperform$73.00 ➝ $72.00
2/25/2022Needham & Company LLCLower TargetBuy$83.00 ➝ $73.00
2/25/2022Piper SandlerLower Target$79.00 ➝ $75.00
10/29/2021Wells Fargo & CompanyBoost TargetEqual Weight$68.00 ➝ $74.00
9/30/2021Barrington ResearchInitiated CoverageBuy$79.00
7/30/2021Barrington ResearchBoost TargetOutperform$71.00 ➝ $79.00
7/30/2021Raymond JamesBoost TargetOutperform$69.00 ➝ $73.00
7/30/2021Needham & Company LLCBoost TargetBuy$73.00 ➝ $83.00
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$65.00 ➝ $68.00
7/30/2021Piper SandlerBoost TargetOverweight$73.00 ➝ $79.00
4/30/2021Needham & Company LLCBoost TargetBuy$68.00 ➝ $73.00
4/30/2021Barrington ResearchBoost TargetOutperform$63.00 ➝ $71.00
4/30/2021Raymond JamesBoost TargetOutperform$61.00 ➝ $69.00
3/3/2021Raymond JamesBoost TargetOutperform$60.00 ➝ $61.00
2/25/2021Needham & Company LLCBoost TargetBuy$65.00 ➝ $68.00
2/25/2021Raymond JamesReiterated RatingOutperform$60.00 ➝ $61.00
2/25/2021Barrington ResearchBoost TargetOutperform$62.00 ➝ $63.00
1/5/2021Needham & Company LLCUpgradeHold ➝ Buy$65.00
11/11/2020Wells Fargo & CompanyBoost TargetEqual Weight$51.00 ➝ $58.00
11/11/2020OppenheimerBoost TargetOutperform$55.00 ➝ $60.00
11/11/2020Raymond JamesBoost TargetOutperform$57.00 ➝ $60.00
10/29/2020SidotiBoost TargetBuy$63.00 ➝ $72.00
10/29/2020Barrington ResearchBoost TargetOutperform$54.00 ➝ $62.00
10/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$42.00 ➝ $51.00
10/29/2020OppenheimerBoost TargetOutperform$50.00 ➝ $55.00
10/29/2020Raymond JamesBoost TargetPositive ➝ Outperform$51.00 ➝ $57.00
10/29/2020Piper SandlerBoost TargetOverweight$55.00 ➝ $62.00
9/28/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$42.00
9/14/2020Raymond JamesReiterated RatingBuy
7/30/2020OppenheimerBoost TargetOutperform$46.00 ➝ $50.00
7/30/2020Raymond JamesBoost TargetOutperform$49.00 ➝ $51.00
7/30/2020Barrington ResearchBoost TargetOutperform$49.00 ➝ $54.00
7/30/2020Needham & Company LLCReiterated RatingHold
7/30/2020Piper SandlerBoost TargetPositive ➝ Overweight$50.00 ➝ $55.00
6/1/2020SidotiBoost TargetBuy$55.00 ➝ $63.00
5/27/2020Barrington ResearchBoost TargetOutperform$42.00 ➝ $49.00
5/27/2020Raymond JamesBoost TargetOutperform$46.00 ➝ $49.00
4/24/2020Barrington ResearchUpgradeBuy$42.00
4/24/2020Raymond JamesBoost TargetOutperform$44.00 ➝ $46.00
4/24/2020Wells Fargo & CompanyBoost TargetUnderweight$33.00 ➝ $37.00
4/24/2020OppenheimerReiterated RatingBuy$46.00
4/20/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform
2/26/2020Needham & Company LLCReiterated RatingHold
2/25/2020Piper SandlerReiterated RatingOverweight$42.00 ➝ $50.00
2/25/2020Barrington ResearchDowngradeOutperform ➝ Market Perform
2/25/2020Wells Fargo & CompanyBoost TargetUnderweight$26.00 ➝ $33.00
2/25/2020Raymond JamesBoost TargetOutperform$43.00 ➝ $47.00
2/7/2020OppenheimerBoost Target$32.00 ➝ $43.00
2/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$43.00
1/14/2020Piper SandlerBoost Target$30.00 ➝ $42.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 17 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 13 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024
  • 16 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/23/2024
  • 22 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2024
  • 12 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2024
  • 33 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2024
  • 36 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/21/2024

Current Sentiment

  • 36 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Merit Medical Systems logo
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Read More

Today's Range

Now: $98.22
Low: $95.51
High: $99.04

50 Day Range

MA: $100.75
Low: $94.90
High: $105.52

52 Week Range

Now: $98.22
Low: $70.70
High: $108.07

Volume

1,433,879 shs

Average Volume

440,105 shs

Market Capitalization

$5.72 billion

P/E Ratio

48.15

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Merit Medical Systems?

The following Wall Street sell-side analysts have issued research reports on Merit Medical Systems in the last year: Baird R W, Bank of America Co., Barrington Research, Canaccord Genuity Group Inc., CL King, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for MMSI.

What is the current price target for Merit Medical Systems?

0 Wall Street analysts have set twelve-month price targets for Merit Medical Systems in the last year. Their average twelve-month price target is $105.60, suggesting a possible upside of 7.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting MMSI will reach $127.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $87.00 for Merit Medical Systems in the next year.
View the latest price targets for MMSI.

What is the current consensus analyst rating for Merit Medical Systems?

Merit Medical Systems currently has 1 hold rating, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MMSI will outperform the market and that investors should add to their positions of Merit Medical Systems.
View the latest ratings for MMSI.

What other companies compete with Merit Medical Systems?

How do I contact Merit Medical Systems' investor relations team?

Merit Medical Systems' physical mailing address is 1600 WEST MERIT PARK WAY, SOUTH JORDAN UT, 84095. The medical instruments supplier's listed phone number is (801) 253-1600 and its investor relations email address is [email protected]. The official website for Merit Medical Systems is www.merit.com. Learn More about contacing Merit Medical Systems investor relations.